Current Regulatory Guidelines for Human Biospecimens & Patient Consent in Clinical Research, New Webinar Hosted by Xtalks
TORONTO, June 25, 2018 (Newswire.com) - A biomarker-driven, precision medicine-based approach is becoming more prevalent in drug development and associated(https://verymuchyoung.top) clinical trial design. Since biospecimen-derived biomarker measurements determine patient segmentation and endpoints in these trials, accurate biospecimen (sample) lifecycle management and real-time consent reconciliation are critical considerations in successfully meeting the outcomes of clinical development projects.
In this live webinar, Lorrie Divers, President of QRCP Solutions, and Mark Engelhart, Chief Commercial Officer of BioFortis, will summarize and discuss key regulatory requirements for consideration as organizations(https://klausskovbo.com) design, conduct and submit clinical trial-based research.
Key takeaways include:
Join this informative and interactive presentation on Wednesday, July 11, 2018, at 2 p.m. EDT.
To learn more about this complimentary event, visit Current Regulatory Guidelines for Human Biospecimens & Patient Consent in Clinical Research.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands(https://cgnatureng.com) of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content.
Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
评论
发表评论